News >

Expert Shares Optimism on Surgical Advances in Melanoma

Jonathan Alicea and Gina Columbus
Published: Monday, Jul 24, 2017

Russell Berman, MD

Russell Berman, MD
Practitioners today are having much different conversations than they did in the past regarding the treatment options for patients with melanoma who have non-nodal metastases or regionally advanced disease, according to Russell Berman, MD. Moreover, thanks to refined techniques, select patients who were not deemed eligible for surgery are now able to undergo it.

on Melanoma and Immuno-Oncology, Berman, division chief of Surgical Oncology at New York University Langone Medical Center in New York, shared his enthusiasm over ongoing surgical advances in the treatment of melanoma.

OncLive: What did you discuss in your lecture on melanoma?

Berman: I spoke about non-nodal regional metastases, which, in melanoma, we refer to as in-transit metastases. I also spoke a little bit about systemic metastasis. Now, what is fascinating is that, with new systemic therapies that are effective for melanoma, such as the checkpoint inhibitors in targeted therapy, people think, “Well, is surgery no longer applicable? Do we ever need it again?” In fact, it may actually be defining a role for surgery that we didn't previously appreciate.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication